Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Ginekologia Polska
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2023

open access

Vol 81, No 3 (2010)
ARTICLES
View PDF Download PDF file
Get Citation

Influence of tamoxifen on cisplatin-sensitivity and estrogen receptors expression in ovarian carcinoma cell lines

Ewa Nowak-Markwitz, Adam Maciejczyk, Marek Pudełko, Gansukh Tserenchunt, Gyorffy Balazs, Marek Spaczyński, Maciej Zabel, Manfred Dietel, Hermann Lage, Paweł Surowiak
Ginekol Pol 2010;81(3).

open access

Vol 81, No 3 (2010)
ARTICLES

Abstract

Abstract Background: Tamoxifen, used in breast cancer treatment, competitively inhibits estrogen receptor (ER) and also demonstrates direct antiproliferative effect on cancer cells even in ER lacking cancer tissue. However, its molecular mechanism of action is still unclear. Material and methods: We exposed on tamoxifen 11 ovarian cancer cell lines, including well-documented platinumsensitive and platinum-resistant ones, and studied tamoxifen-, cisplatin-sensitivity and expression of ERα and s. Results: We observed: no correlation between TAM-sensitivity and ERα and ERs expressions, no correlation between TAM influence on cisplatin-sensitivity and ERα and ERs expressions, increase of ERs expression after TAM-exposure in 3 cell lines; decrease in the 1 line, no TAM-exposure influence on ERα expression and increase of IC50 for cisplatin after TAM-exposure in 5 (45%) cell lines. These results show ovarian cancer cells being affected by TAM have different platinum sensitivity. Conclusions: Our data suggests that ovarian cancer cells platinum-sensitivity are not linked with ER expressions. We claim the necessity of seeking some TAM predicting factors, using DNA microarrays.

Abstract

Abstract Background: Tamoxifen, used in breast cancer treatment, competitively inhibits estrogen receptor (ER) and also demonstrates direct antiproliferative effect on cancer cells even in ER lacking cancer tissue. However, its molecular mechanism of action is still unclear. Material and methods: We exposed on tamoxifen 11 ovarian cancer cell lines, including well-documented platinumsensitive and platinum-resistant ones, and studied tamoxifen-, cisplatin-sensitivity and expression of ERα and s. Results: We observed: no correlation between TAM-sensitivity and ERα and ERs expressions, no correlation between TAM influence on cisplatin-sensitivity and ERα and ERs expressions, increase of ERs expression after TAM-exposure in 3 cell lines; decrease in the 1 line, no TAM-exposure influence on ERα expression and increase of IC50 for cisplatin after TAM-exposure in 5 (45%) cell lines. These results show ovarian cancer cells being affected by TAM have different platinum sensitivity. Conclusions: Our data suggests that ovarian cancer cells platinum-sensitivity are not linked with ER expressions. We claim the necessity of seeking some TAM predicting factors, using DNA microarrays.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

ovarian carcinoma, cisplatin, tamoxifen, Estrogen Receptor alpha

About this article
Title

Influence of tamoxifen on cisplatin-sensitivity and estrogen receptors expression in ovarian carcinoma cell lines

Journal

Ginekologia Polska

Issue

Vol 81, No 3 (2010)

Page views

639

Article views/downloads

780

Bibliographic record

Ginekol Pol 2010;81(3).

Keywords

ovarian carcinoma
cisplatin
tamoxifen
Estrogen Receptor alpha

Authors

Ewa Nowak-Markwitz
Adam Maciejczyk
Marek Pudełko
Gansukh Tserenchunt
Gyorffy Balazs
Marek Spaczyński
Maciej Zabel
Manfred Dietel
Hermann Lage
Paweł Surowiak

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl